{
    "clinical_study": {
        "@rank": "127841", 
        "arm_group": [
            {
                "arm_group_label": "Water", 
                "arm_group_type": "Placebo Comparator", 
                "description": "200 mL of water once a day for 14 days"
            }, 
            {
                "arm_group_label": "Rifampin", 
                "arm_group_type": "Active Comparator", 
                "description": "Rifampin 600 mg once a day for 14 days"
            }, 
            {
                "arm_group_label": "Grapefruit Juice", 
                "arm_group_type": "Active Comparator", 
                "description": "200 mL of grapefruit juice once a day for 14 days"
            }, 
            {
                "arm_group_label": "Grapefruit Juice Plus Rifampin", 
                "arm_group_type": "Active Comparator", 
                "description": "200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days"
            }, 
            {
                "arm_group_label": "Clarithromycin", 
                "arm_group_type": "Active Comparator", 
                "description": "Clarithromycin 250 mg twice a day for 14 days"
            }, 
            {
                "arm_group_label": "Clarithromycin Plus Rifampin", 
                "arm_group_type": "Active Comparator", 
                "description": "Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether changes in the activity of the enzyme\n      CYP3A4 can change the Vitamin D and bone mineral homeostasis."
        }, 
        "brief_title": "CYP3A4 Induction and Mineral Homeostasis", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Vitamin D and Calcium Homeostasis", 
        "detailed_description": {
            "textblock": "Healthy volunteers will receive one of six interventions for 14 days (determined by\n      randomization):a). 200 mL of water once a day; b) rifampin 600 mg once a day; c) 200 mL of\n      grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days; d)\n      clarithromycin 250 mg twice a day; f) clarithromycin 250 mg twice a day plus rifampin 600 mg\n      once a day."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with no history of significant medical conditions including cardiac,\n             pulmonary, gastrointestinal, or renal disease, HIV, diabetes mellitus or Hepatitis B\n             or C\n\n          -  Subjects will be males or females 18-60 years of age\n\n          -  Subjects must read and understand English\n\n          -  Subjects must be able to provide informed consent\n\n          -  Subjects must be willing to avoid prescription medications, OTC drugs, dietary\n             supplements and foods that are known to modulate CYP3A4 expression or activity\n\n          -  Subjects must be willing to maintain a consistent consumption of calcium and Vitamin\n             D during the study and maintain a daily logbook of their dietary consumption\n\n          -  Women not currently pregnant or lactating. In addition, women participants of\n             childbearing age must be willing to utilize a barrier method of birth control\n             (sterilization will be acceptable)\n\n          -  Subjects will have no known allergies to the study drugs to be used\n\n          -  Subject's corrected QTc interval obtained by electrocardiogram will be \u2264 430 ms in\n             men or \u2264 450 ms in women\n\n        Exclusion Criteria:\n\n          -  Subjects with any significant chronic medical condition, including cardiac,\n             pulmonary, gastrointestinal, or renal disease, HIV, diabetes mellitus or Hepatitis B\n             or C\n\n          -  Subjects less than 18 or greater than 60 years of age\n\n          -  Subjects unable to read and understand English\n\n          -  Subjects unable to provide informed consent\n\n          -  Subjects unable to avoid prescription medications, OTC drugs, dietary supplements and\n             foods that are known to modulate CYP3A4 expression or activity\n\n          -  Subjects not willing to maintain a consistent consumption of calcium and Vitamin D\n             during the study and maintain a daily logbook of their dietary consumption\n\n          -  Women who are pregnant or lactating and women participants of childbearing age not\n             willing to utilize a barrier method of birth control (sterilization will be\n             acceptable)\n\n          -  Subjects with allergies to rifampin, clarithromycin or grapefruit juice\n\n          -  Potential participants will be excluded if they are concurrently participating in\n             another research study\n\n          -  Subjects with corrected QTc interval  > 430 ms in men or > 450 ms in women on\n             electrocardiogram"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019875", 
            "org_study_id": "R01GM063666"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Rifampin", 
                    "Grapefruit Juice Plus Rifampin", 
                    "Clarithromycin Plus Rifampin"
                ], 
                "intervention_name": "Rifampin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Clarithromycin", 
                    "Clarithromycin Plus Rifampin"
                ], 
                "intervention_name": "Clarithromycin", 
                "intervention_type": "Drug", 
                "other_name": "Biaxin"
            }, 
            {
                "arm_group_label": [
                    "Grapefruit Juice", 
                    "Grapefruit Juice Plus Rifampin"
                ], 
                "intervention_name": "Grapefruit Juice", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rifampin", 
                "Clarithromycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Vitamin D", 
            "CYP3A4", 
            "Calcium"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": {
            "contact": {
                "email": "carolc3@u.washington.edu", 
                "last_name": "Carol Collins, M.D.", 
                "phone": "206-616-3294"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98815"
                }, 
                "name": "University of Washington"
            }, 
            "investigator": [
                {
                    "last_name": "Kenneth Thummel, Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Carol Collins, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ian De Boer, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Hormonal Regulation of CYP3A", 
        "overall_official": {
            "affiliation": "University of Washington", 
            "last_name": "Kenneth Thummel, Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Serum", 
                "measure": "1, 25(OH) D3 Vitamin D", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }, 
            {
                "description": "Serum", 
                "measure": "25(OH) D3 Vitamin D", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }, 
            {
                "description": "Blood", 
                "measure": "Parathyroid Hormone", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }, 
            {
                "description": "Serum", 
                "measure": "Osteocalcin", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }, 
            {
                "description": "Serum", 
                "measure": "Calcium, total", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }, 
            {
                "description": "Serum", 
                "measure": "Calcium, ionized", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }, 
            {
                "description": "Urine", 
                "measure": "Calcium", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }, 
            {
                "description": "Urine", 
                "measure": "Phosphate", 
                "safety_issue": "No", 
                "time_frame": "Samples will be collected on day 1, day 4, day 7, day 8 (first day of intervention), day 9, day 11, day 15, day 18, day 22 (last day of intervention), day 24, day 26, day 29, day 32 and day 36."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019875"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Washington", 
            "investigator_full_name": "Kenneth Thummel", 
            "investigator_title": "Professor and Chair, Department of Pharmaceutics", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Washington", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Washington", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}